Cytoki Pharma

Cytoki Pharma is a biotechnology company that specializes in developing novel medicines for diseases with a significant unmet medical need with a focus on serious diseases caused by epithelial injury. CytoKi Pharma is a pre-clinical biotechnology company with focus on serious diseases caused by epithelial injury having an unmet medical need. Cytoki’s lead program is an engineered long-acting IL-22 protein licensed from a major pharmaceutical company.A correctly functioning immune system is essential for keeping us healthy in the multitude of challenges our organism encounters. Numerous medicines are based on principles that activate or deactivate key proteins in the immune system in a disease context. IL-22 is a key cytokine (a class of proteins released from immune cells) in securing the survival and repair after an injury. It is the immune system’s “Survive and Recover” signal to the tissue. Our lead program is harnessing the power of IL-22, in treatment of organ injuries, through a modified IL-22 protein engineered to have optimal pharmaceutical properties.

Cytoki Pharma headquartered in Europe, operates in the Biotechnology, Life Science sector. The company focuses on Biotechnology and has secured $360.0M in funding across 8 round(s). With a team of 1-10 employees, Cytoki Pharma is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Cytoki Pharma, raised $45.0M. Discover more about their projects, partnerships, and impact on our platform.